Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins

NCT06595680 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

End Stage Renal Disease
Chronic Hemolysis

Interventions

DRUG: Medialipide 20% perfusion
DRUG: NaCl 0,9%
BIOLOGICAL: Blood sample

Sponsor

Hospices Civils de Lyon